Penn Gene Therapy Silences Pain Without Opioids
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Pennsylvania researchers developed a CNS‑targeted gene therapy that silences pain signals by introducing a synthetic opioid promoter, mimicking morphine’s analgesia without triggering reward pathways.
- AI mapping of cortical pain circuits guided the design of the therapy, allowing precise targeting of the brain regions that morphine acts on while preserving normal sensation.
- Preclinical mouse studies showed the therapy provided sustained pain relief without affecting normal touch perception or causing addiction‑like behavior.
- Nature published the findings (2026; 649 (8098): 938), and the work was funded by multiple NIH grants, including a New Innovator Award.
- Gregory Corder and Michael Platt outlined plans to advance the therapy toward clinical trials, emphasizing its potential to address the opioid crisis.
- Provisional patent filed by Penn and Stanford covers the custom synthetic opioid promoter sequences used in the therapy.
- Chronic pain affects about 50 million Americans and incurs $635 million in annual costs; the therapy could reduce this burden by offering non‑addictive relief.
Why it matters: Patients with chronic pain—over 50 million Americans—could gain effective relief without opioid risks, while the opioid market may see reduced demand; the therapy also offers a new avenue for non‑addictive analgesics, potentially lowering the $635 million annual cost of chronic pain and improving quality of life.
